Paris, 31 october 2025 – Substipharm strengthens its portfolio with the acquisition of iconic brands Aspégic® from Opella and Kardégic® / Cardirene®from Sanofi
Paris, 31 october 2025 – Substipharm announces the acquisition of two well-known pharmaceutical brands: Aspégic®, acquired from Opella, and Kardégic® / Cardirene®, acquired from Sanofi. Both brands have been trusted by healthcare professionals and patients for decades in the fields of pain relief, inflammation, fever management, and cardiovascular prevention. A strategic transaction combining heritage and […]
CPHI Frankfurt
We are thrilled to announce that the Substipharm global team will be present at CPHI Frankfurt! 🚀 This year, we’re bringing together our full strength to connect, collaborate, and share our expertise. You’ll have the chance to meet: Our Business Development team Our Alliance Management team Our Customer Services team Our Supply team Our Industrial […]
Medigen Vaccine Biologics Corp Collaborates with Substipharm Biologics Expanding ENVACGEN® Enterovirus A71 Vaccine Market in Southeast Asia
[Taipei, Taiwan & Geneva, Switzerland] January 9, 2025 Medigen Vaccine Biologics Corp (MVC) has signed a regional distribution agreement with the pharmaceutical company Substipharm Biologics to expand the market reach of enterovirus vaccine products in Southeast Asia. The two companies have finalized an exclusive distribution agreement for ENVACGEN® Enterovirus A71 (EV-A71) vaccine in Vietnam as […]
30 Years. One Family. One Mission.
Across generations, Substipharm has remained faithful to its essence. What began with a commitment to developing generics has flourished into a broader journey — spanning diverse therapeutic areas, embracing established medicines, pioneering biologics, and charting our own path in commercialization.Through it all, one thing has never changed: our unwavering dedication to health and accessibility, the true […]